Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System
AC5 Advanced Wound System is indicated for the management of partial and full-thickness wounds, such as pressure sores, venous leg ulcers, diabetic foot ulcers, and surgical wounds.
- AC5 Advanced Wound System is indicated for the management of partial and full-thickness wounds, such as pressure sores, venous leg ulcers, diabetic foot ulcers, and surgical wounds.
- The inclusion of AC5 on the Federal Supply Schedule, in concert with our previously announced DAPA and ECAT awards, greatly expands the accessibility and ease of procurement of AC5, which will now be available for patients at all federal government facilities, stated Terry Norchi, MD, Chief Executive Officer of Arch Therapeutics.
- Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively.
- Lovells mission is to serve the Veterans Administration (VA) Hospital System, the U.S. Military Medical Networks, other Federal Healthcare Systems, and thecommunities they support.